FDA Antihypertensive Draft Class Labeling To Be Reviewed By Cardio-Renal Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s proposal for relabeling of antihypertensive agents is based on prior recommendations by the committee that information on cardiovascular outcomes related to blood pressure lowering be included as class labeling.
You may also be interested in...
Antihypertensive Class Labeling Public Health Impact Assessment Being Considered By FDA
Class labeling for antihypertensives on blood pressure reduction and cardiovascular outcomes to be discussed during an April 26 meeting.
Antihypertensive Class Labeling Public Health Impact Assessment Being Considered By FDA
Class labeling for antihypertensives on blood pressure reduction and cardiovascular outcomes to be discussed during an April 26 meeting.
Cellegy Cellegesic Re-Analysis Of Anal Fissure Pain Relief Data Slated For Committee Review
FDA takes Cellegesic data analyses on pain reduction and fissure healing to cardio-renal advisory committee following protracted review.